Monitor upcoming clinical trial results for CTM-N2D, which could be a catalyst for the stock. The company's cash position appears sufficient for near-term operations, but future financing may be needed for later-stage trials.
Price Chart
Executive Summary
CytoMed Therapeutics' 20-F filing confirms ongoing Phase I clinical trials for its lead product candidate CTM-N2D, with patient dosing completed at two dosage levels. The company reported $324,387 in revenue from private blood banking services in 2025 and has sufficient resources to fund operations into 2026. Recent 6-K filings confirm clinical progress and refute misleading claims about the company's programs.
Key Facts
- Ongoing Phase I ANGELICA Trial for CTM-N2D with six patients treated at two dosage levels
- Revenue of $324,387 from private blood banking services in 2025
- Cash balance of $2.10 million as of December 31, 2025
- Sufficient resources to fund operations into 2026
- Recent 6-K filings confirm clinical progress and refute misleading claims
Financial Impact
Revenue of $324,387 from private blood banking services in 2025, with cash balance of $2.10 million
Risk Factors
- Biotech companies with no approved products face high risk of failure
- Clinical trial results may not meet expectations
- Need for future financing could lead to dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001493152-26-013813 |
| Exhibit: ex2-1.htm | 0001493152-26-013813 |
| Exhibit: ex12-1.htm | 0001493152-26-013813 |
| Exhibit: ex12-2.htm | 0001493152-26-013813 |
| Exhibit: ex13-2.htm | 0001493152-26-013813 |
| Exhibit: ex13-1.htm | 0001493152-26-013813 |
| Exhibit: ex15-1.htm | 0001493152-26-013813 |
| Document: 0001493152-26-013813-index-headers.html | 0001493152-26-013813 |
| Document: 0001493152-26-013813-index.html | 0001493152-26-013813 |
| Document: 0001493152-26-013813.txt | 0001493152-26-013813 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | SC 13G/A | $0.9190 $0.9262 | ▲ +0.78% | ▲ +0.07% | $0.8653 (−5.84%) |
Oct 16, 2026 11d ago | SC 13D/A | $0.8799 $0.8520 | ▼ −3.17% | ▼ −3.59% | $0.8653 (−1.66%) |
Oct 13, 2026 14d ago | SC 13D/A | $0.8700 $0.8599 | ▼ −1.16% | ▼ −0.08% | $0.8653 (−0.54%) |
Oct 9, 2026 17d ago | 6-K | $0.8114 $0.8700 | ▼ −7.22% | ▼ −7.23% | $0.8653 (−6.64%) |
Sep 30, 2026 27d ago | 6-K | $0.8430 $0.8999 | ▼ −6.75% | ▼ −6.57% | $0.8653 (−2.65%) |
May 15, 2026 23w ago | 6-K | $1.16 $1.21 | ▲ +4.31% | ▲ +4.37% | $0.8653 (−25.41%) |
May 11, 2026 24w ago | 6-K | $0.8090 $0.7690 | ▼ −4.94% | ▼ −4.81% | $0.8653 (+6.96%) |
Mar 31, 2026 30w ago | 6-K | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.8653 (−13.47%) |
Mar 31, 2026 30w ago | 20-F | $1.00 $1.03 | ▲ +3.00% | ▲ +2.25% | $0.8653 (−13.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers